

JCS44 U.S. PTO
01/14/98

Patent
PC7981C
1.53(b)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

This is a request for filing a [] continuation [X] divisional application under 37 CFR § 1.53(b), of pending prior application serial no. 08/167,881, filed on 12/14/93, of John A. Lowe, III et al. for Fluoroalkoxybenzylamino Derivatives of Nitrogen Containing Heterocycles, which is the U.S. National phase of International Application PCT/US 92/03571, filed on 5/5/92.

1. [X] Enclosed is a copy of the present application (specification = 58 pages, claims = 11 pages and abstract = 1 page). The present application, Pfizer docket no. PC7981C, has the same title as, and identical inventorship to prior application 08/167,881.
2. [X] Also enclosed is a copy of the prior application, including the oath or declaration as originally filed and an affidavit or declaration verifying it as a true copy.

"Express Mail" mailing label number NB15211085X
Date of Deposit 1/14/98

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D. C. 20231.

Karen DeBenedictis
(Typed or printed name of person mailing paper or fee)
Karen DeBenedictis
(Signature of person mailing paper or fee)

1/92
M.12
(1/3)

3. ☒ The filing fee is calculated below:

CLAIMS AS FILED IN THE PRIOR APPLICATION, LESS ANY
CLAIMS CANCELLED BY AMENDMENT BELOW

<u>FOR</u>	<u>NUMBER FILED</u>	<u>NUMBER EXTRA</u>	<u>RATE</u>	<u>BASIC FEE \$790.00</u>
Total Claims	<u>45</u> -20 =	<u>25</u>	X \$22.00	<u>\$264.00</u>
Independent Claims	<u>3</u> =	<u>0</u>	X \$76.00	<u>0.00</u>
Multiple Dependent Claim(s) fee (\$240.00)				<u>0.00</u>
Total Filing Fee				<u>\$1054.00</u>

4. ☒ Please charge Deposit Account No. 16-1445 in the amount of \$1054.00. Two copies of this sheet are enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required under 37 C.F.R. 1.16 and 1.17, or credit any overpayment to Account No. 16-1445. Two copies of this sheet are enclosed.
5. ☒ Priority of application serial no. 08/167,881 is claimed. Such application was filed in the U.S.P.T.O. on December 14, 1993 as the U.S. national phase of International Application PCT/US 92/03571, which was filed on 5/5/92.
6. ☒ The prior application is assigned of record to Pfizer Inc.
7. ☒ The power of attorney in the prior application is to (See the list of attorneys and agents that appears on the enclosed copy of the Combined Declaration and Power of Attorney Form that was filed with application 08/167,881 on 12/14/93).
- a. ☒ The power appears in the original papers in the prior application.
- b. ☒ A copy of the power in the prior application is enclosed.

1/92
M.12
(2/3)

- c. ☒ Address all future communications to Peter C. Richardson, Pfizer Inc., 235 East 42nd Street, New York, New York 10017-5755. (May only be completed by applicant, or attorney or agent of record.)
8. ☒ I hereby verify that the attached papers so designated are a true copy of prior application serial no. 08/167,881 as originally filed in the U.S. Receiving Office as International Application PCT/US 92/03571 on 5/5/92, and of the Declaration and Power of Attorney form and accompanying documents filed in the U.S.P.T.O. on December 12, 1993.

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1/14/98
(date)

Karen DeBenedictis
(signature)

Pfizer Inc.
Patent Dept.
235 East 42nd Street
New York, N.Y. 10017-5755
(212) 573-5425

☐ Inventor(s)
☐ Assignee of complete interest
☒ Attorney or agent of record,
Reg. No. 32,977
☐ Filed under § 1.34(a)

Copy of National Phase Filing Papers for Prior

JC546 U.S. PTC
09/08/98
01/13/98

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER PC 7981A	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.50)	
INTERNATIONAL APPLICATION NO. PCT/US 92/03571	INTERNATIONAL FILING DATE May 5, 1992	PRIORITY DATE CLAIMED June 20, 1991	
TITLE OF INVENTION FLUOROALKOXYBENZYLAMINO DERIVATIVES OF NITROGEN CONTAINING HETEROCYCLES			
APPLICANT(S) FOR DO/EO/US John A. Lowe, III and Terry J. Rosen			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is the FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is the SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p> b. <input type="checkbox"/> has been transmitted by the International Bureau.</p> <p> c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p> b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p> c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p> d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
Items 11. to 16. below concern other document(s) or information included:			
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.</p> <p>12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p> <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input type="checkbox"/> Other items or information.</p>			

EXPRESS MAIL NO. RB951237364

17. ☒ The following fees are submitted:

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

- ☒ Search Report has been prepared by the EPO or JPO \$830.00
 International preliminary examination fee paid to USPTO (37 CFR 1.482) \$640.00
 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00
 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$950.00
 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$ 90.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS

PTO USE ONLY

\$ 830.00

Surcharge of \$130.00 for furnishing the oath or declaration later than __ -20 __ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 0.00

CLAIMS

NUMBER FILED

NUMBER EXTRA

RATE

Total Claims

43 - 20 =

23

X \$ 22.00

\$ 506.00

Independent Claims

2 - 3 =

0

X \$ 74.00

\$ 0.00

Multiple dependent claim(s) (if applicable)

X \$230.00

\$ 0.00

TOTAL OF ABOVE CALCULATIONS =

\$ 1336.00

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note: 37 CFR 1.9, 1.27, 1.28)

\$ 0.00

SUBTOTAL =

\$ 1336.00

Processing fee of \$130.00 for furnishing the English translation later than __ 20 __ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

+

\$ 0.00

TOTAL NATIONAL FEE =

\$ 1336.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

+

\$ 40.00

TOTAL FEES ENCLOSED =

\$ 1376.00

Amount to be refunded:

\$

Charged

\$

- a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.
 b. ☒ Please charge my Deposit Account No. 16-1445 in the amount of \$1376.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
 c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 16-1445. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Dr. Peter C. Richardson
 Pfizer Inc
 Patent Dept., 20th Floor
 235 East 42nd Street
 New York, NY 10017-5755

SIGNATURE

Karen DeBenedictis

NAME

32,977

REGISTRATION NUMBER